Drug treatment status and research progress on triple-negative breast cancer
10.11904/j.issn.1002-3070.2015.01.020
- VernacularTitle:三阴性乳腺癌的药物治疗现状及研究进展
- Author:
Jianing LUO
;
Xiaofeng GE
- Publication Type:Journal Article
- Keywords:
TNBC;
Chemotherapy;
Targeted therapy
- From:
Practical Oncology Journal
2015;(1):89-92
- CountryChina
- Language:Chinese
-
Abstract:
Triple negative breast cancer ( TNBC) is defined by the lack of expressions of the estrogen re-ceptor(ER)、progesterone receptor(PR)and human epidermal growth factor receptor 2(HER-2).Although it is sensitive to radiation and chemotherapy ,it lacks of appropriate targeted therapy and endocrine therapy .It performs characteristics of the strong invasion ,high risk of recurrence and poor prognosis .So in recent years ,triple negative breast cancer gets more and more attention from international oncology community .In-depth study of triple nega-tive breast cancer will help the prevention ,early diagnosis ,judge the progress of the disease and improve progno-sis.TNBC drug treatment and relevant research progress are reviewed in the present article .
